Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / *W EXP 99/99/999
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
1.88M
-
Shares change
-
-352K
-
Total reported value, excl. options
-
$3.94M
-
Value change
-
-$678K
-
Number of buys
-
3
-
Number of sells
-
-5
-
Price
-
$2.09
Significant Holders of NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) as of Q2 2023
21 filings reported holding NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 as of Q2 2023.
NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.88M shares
.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (500K shares), HIGHBRIDGE CAPITAL MANAGEMENT LLC (462K shares), RA CAPITAL MANAGEMENT, L.P. (333K shares), Ensign Peak Advisors, Inc (150K shares), Bain Capital Life Sciences Investors, LLC (100K shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (92.8K shares), Affinity Asset Advisors, LLC (37K shares), Walleye Capital LLC (32.3K shares), Westchester Capital Management, LLC (31.2K shares), and HRT FINANCIAL LP (30.3K shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.